perzebertinib   Click here for help

GtoPdb Ligand ID: 13741

Synonyms: example 31 [WO2020057511A1] | ZN-1041 | ZN-A-1041 | ZNA-1041
Compound class: Synthetic organic
Comment: The chemical structure for perzebertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. A structure search in PubChem identified the company research code ZN-A-1041 (Zion Pharma) as a synonym. ZN-A-1041 is an orally bioavailable tyrosine kinase inhibitor that is intended to target human epidermal growth factor receptor 2 (ERBB2; HER2) in HER2+ve cancers. It can cross the blood-brain barrier so may be effective against brain metastases. This is one of the inhibitors claimed in patent WO2020057511A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 108
Molecular weight 548.54
XLogP 1.34
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=CC=C1OC2=CC3=NC=NN3C=N2)NC4=NC=NC5=CC=C(C(=C54)O[C@@H]6CCN(C)CC6(F)F)OC
Isomeric SMILES CC1=C(C=CC(=C1)NC2=NC=NC3=C2C(=C(C=C3)OC)O[C@@H]4CCN(CC4(F)F)C)OC5=CC6=NC=NN6C=N5
InChI InChI=1S/C27H26F2N8O3/c1-16-10-17(4-6-19(16)39-23-11-22-31-14-34-37(22)15-33-23)35-26-24-18(30-13-32-26)5-7-20(38-3)25(24)40-21-8-9-36(2)12-27(21,28)29/h4-7,10-11,13-15,21H,8-9,12H2,1-3H3,(H,30,32,35)/t21-/m1/s1
InChI Key PTKRHBXNNDLRPO-OAQYLSRUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Zhou D, Cheng Z. (2020)
Quinazoline derivatives as antitumor agents.
Patent number: WO2020057511A1. Assignee: Suzhou Zanrong Pharma Limited. Priority date: 19/02/2019. Publication date: 26/03/2020.